The Format That Changed the Price Floor
For the first two years of the compounded GLP-1 boom, "compounded semaglutide" meant one thing: a sterile injectable in a vial. The compounding process — cleanroom preparation, sterility testing, cold-chain shipping — set a cost floor that kept monthly prices above $149 at most legitimate providers.
Then oral formats arrived. Sublingual drops placed under the tongue. Troches that dissolve in the cheek. Tablets swallowed daily. These formulations do not require sterile compounding, sharps supplies, or cold-chain shipping. The result: a new price tier that undercuts injectables by 30–50%.
Oral GLP-1 Format Breakdown
| Format | How It Works | Frequency | Bioavailability |
|---|---|---|---|
| Sublingual drops | Liquid placed under tongue, absorbed through oral mucosa | Daily | Moderate (higher than swallowed pill) |
| Troches / lozenges | Dissolving lozenge held in cheek for buccal absorption | Daily | Moderate |
| Dissolving tablets (ODT) | Tablet dissolves on tongue, partially sublingual absorption | Daily | Moderate |
| Swallowed tablets | Standard oral tablet absorbed through GI tract | Daily | Lower (significant GI degradation) |
| Injectable (for comparison) | Subcutaneous injection, direct bloodstream | Weekly | High (~95%+) |
💡 Bioavailability is the critical variable. Injectable semaglutide delivers nearly 100% of the dose to your bloodstream. Oral formats absorb 10–40% depending on the formulation and individual physiology. Prescribers compensate by prescribing higher absolute doses in oral formats — which is why oral pricing per-milligram may look higher even when the monthly cost is lower.
Current Oral Pricing Across Providers
| Provider | Format | Medication | Monthly Price |
|---|---|---|---|
| Telos Rx | Oral tirzepatide | Tirzepatide | From $49/mo (12-mo plan) |
| MadeMed | Oral semaglutide | Semaglutide | $169/mo |
| MadeMed | Oral tirzepatide | Tirzepatide | Contact |
| GobyMeds | Injectable (comparison) | Semaglutide | $99/mo |
| Trimi | Injectable (comparison) | Semaglutide | $99/mo |
Why Oral Formats Cost Less to Compound
The price difference between oral and injectable GLP-1 formats is not arbitrary — it reflects genuine differences in compounding complexity and overhead:
| Cost Driver | Injectable | Oral (Troche/Sublingual) |
|---|---|---|
| Cleanroom requirement | ISO 5 cleanroom (mandatory) | Not required |
| Sterility testing | Required for every batch | Not required |
| Cold-chain shipping | Required (temperature-sensitive) | Usually not required |
| Supplies (syringes, sharps) | Included in patient kit | None needed |
| Compounding time | Higher (aseptic technique) | Lower (standard mixing) |
| Estimated pharmacy cost | $25–$60/vial | $10–$30/batch |
The savings are structural, not a quality shortcut. Oral compounding simply involves fewer regulated steps, less specialized equipment, and simpler logistics. Those savings flow through to the patient.
The Bioavailability Trade-Off
The biggest question about oral GLP-1 formats is whether lower bioavailability translates to lower efficacy. The honest answer: it depends.
What the Data Suggests
- Sublingual and buccal absorption bypasses the GI tract, delivering the peptide directly to the bloodstream through oral mucosa. This route typically achieves 15–40% bioavailability — significantly lower than injection but meaningfully higher than a swallowed tablet.
- Prescribers account for this by increasing the absolute dose. A patient who would receive 1mg injectable semaglutide weekly might receive 3–5mg daily via sublingual format.
- Patient-reported outcomes vary. Some patients report comparable appetite suppression and weight loss on oral formats; others find them less effective than injections at equivalent clinical effort.
💡 If you are considering an oral format primarily for cost savings, discuss with your prescriber whether the lower bioavailability matters for your specific goals. For some patients, the convenience of a daily dissolving tablet plus the cost savings makes oral the clear winner. For others — especially those who need maximum dose-response — injectable remains the gold standard.
Who Should Consider Oral Formats
- Needle-averse patients. The number-one reason patients choose oral formats. If weekly injections cause anxiety, avoidance, or non-adherence, an oral format you actually take consistently will outperform an injection you skip.
- Budget-conscious patients. At $49–$169/month versus $99–$299 for injectables, oral formats can save $600–$1,500+ annually.
- Patients who travel frequently. Oral formats do not require refrigeration, sharps disposal, or TSA explanations. They travel like any other pill.
- Patients with injection-site reactions. Some patients develop irritation, nodules, or bruising at injection sites. Oral formats eliminate this entirely.
Who Should Stick With Injectables
- Patients who respond well to weekly injections. If your current injectable regimen is producing results and you are comfortable with the format, switching to oral for cost savings alone may disrupt a working protocol.
- Patients on high maintenance doses. At higher doses, the bioavailability gap may become clinically significant. Your prescriber can advise.
- Patients who prefer weekly dosing. Oral formats typically require daily administration. If you prefer one injection per week over daily pills, the convenience calculus flips.
The Bottom Line
Oral GLP-1 formats have opened a new pricing tier below the injectable floor. For needle-averse or budget-conscious patients, sublingual drops and troches offer a legitimate path to GLP-1 therapy at 30–50% less than comparable injectables. The trade-off is lower bioavailability requiring adjusted dosing and daily (rather than weekly) administration. If your prescriber supports it and the format works for your lifestyle, oral GLP-1s represent the best value-per-dollar in the current market.
⚠️ Compounded GLP-1 medications — including oral formats — are not FDA-approved. There is no FDA-approved oral tirzepatide. Oral semaglutide is available as a brand-name product (Rybelsus, Wegovy oral) but compounded oral semaglutide is a different product. Always consult a licensed clinician before starting any GLP-1 therapy.